Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 52571, Saudi Arabia.
Molecules. 2022 Sep 10;27(18):5889. doi: 10.3390/molecules27185889.
Cancer is the most commonly diagnosed type of disease and a major cause of death worldwide. Despite advancement in various treatment modules, there has been little improvement in survival rates and side effects associated with this disease. Medicinal plants or their bioactive compounds have been extensively studied for their anticancer potential. Novel drugs based on natural products are urgently needed to manage cancer through attenuation of different cell signaling pathways. In this regard, berberine is a bioactive alkaloid that is found in variety of plants, and an inverse association has been revealed between its consumption and cancer. Berberine exhibits an anticancer role through scavenging free radicals, induction of apoptosis, cell cycle arrest, inhibition of angiogenesis, inflammation, PI3K/AKT/mammalian target of rapamycin (mTOR), Wnt/β-catenin, and the MAPK/ERK signaling pathway. In addition, synergistic effects of berberine with anticancer drugs or natural compounds have been proven in several cancers. This review outlines the anticancer effects and mechanisms of action of berberine in different cancers through modulation of various cell signaling pathways. Moreover, the recent developments in the drug delivery systems and synergistic effect of berberine are explained.
癌症是最常见的疾病类型,也是全球主要的死亡原因。尽管在各种治疗模块方面取得了进展,但生存率和与该疾病相关的副作用几乎没有改善。药用植物或其生物活性化合物因其抗癌潜力而得到广泛研究。迫切需要基于天然产物的新型药物来通过衰减不同的细胞信号通路来治疗癌症。在这方面,小檗碱是一种存在于多种植物中的生物活性生物碱,其摄入量与癌症之间存在反比关系。小檗碱通过清除自由基、诱导细胞凋亡、细胞周期阻滞、抑制血管生成、炎症、PI3K/AKT/哺乳动物雷帕霉素靶蛋白(mTOR)、Wnt/β-catenin 和 MAPK/ERK 信号通路发挥抗癌作用。此外,小檗碱与几种癌症中的抗癌药物或天然化合物的协同作用已得到证实。本综述通过调节各种细胞信号通路,概述了小檗碱在不同癌症中的抗癌作用和作用机制。此外,还解释了小檗碱在药物传递系统中的最新进展和协同作用。
Anticancer Agents Med Chem. 2013-9
Anticancer Agents Med Chem. 2013-9
Curr Issues Mol Biol. 2025-4-18
Mol Biol Rep. 2025-7-16
Chin Med. 2025-6-9
Int J Mol Sci. 2025-4-28
Molecules. 2021-12-4
Clin Exp Pharmacol Physiol. 2022-1
Evid Based Complement Alternat Med. 2021-5-4
Biochem Pharmacol. 2021-6